Latham & Watkins Advises IDEAYA in its Public Offering of Common Stock

The oncology-focused precision medicine company was advised by a California-based life sciences team.

June 22, 2020

IDEAYA Biosciences, Inc. has announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions. In addition, IDEAYA has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by IDEAYA, are expected to be $100.0 million excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about June 22, 2020, subject to the satisfaction of customary closing conditions. 

Latham & Watkins LLP represents IDEAYA Biosciences, Inc. in the offering with a corporate deal team led by Bay Area partner Mark Roeder, with Bay Area associates Alexander White, Meredith Peake and Madelyn Tarr and Orange County associate Eric Hanzich. Advice was also provided on tax matters by Bay Area partner Grace Lee, with Orange County associate Janet Hsu.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.